#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Mantle cell lymphoma stage II Extra-osseous Ewing's sarcoma metastatic Metastatic gastric cancer Langerhans cell sarcoma Partial lipodystrophy Small intestine adenocarcinoma Cerebral amyloid angiopathy Ichthyosis Congenital nephrogenic diabetes insipidus Gastric cancer Cutaneous lupus erythematosus Alveolar rhabdomyosarcoma Myeloproliferative neoplasm Fms-like tyrosine kinase 3 positive Neuropathy peripheral More trials…

    Learn about Rare Diseases

    Angiosarcoma recurrent – Diagnostics Shprintzen-Goldberg syndrome Primary biliary cholangitis – Trials in Disease Prader-Willi syndrome – Life with Disease Hairy cell leukaemia – Life with Disease Primary hyperoxaluria – Treatment Isodicentric chromosome 15 syndrome – Life with Disease Krabbe’s disease – Life with Disease Breast angiosarcoma metastatic – Trials in Disease Atypical teratoid/rhabdoid tumour of CNS – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Argatroban Monohydrate Pemafibrate E.coli Polysaccharide Pariglasgene Brecaparvovec Entrectinib Disodium Levofolinate Lacutamab Irbesartan Remifentanil Hydrochloride Bempedoic Acid Fludarabine Phosphate Ph. Eur. VENT-03 Gs-1427 Prasugrel Lib-01 Monohydrate Saxagliptin Cilastatin Sodium Dexrazoxane Fluvastatin Sodium Ertapenem Sodium More therapies…

    Learn about Your Condition

    Vascular calcification IgA nephropathy Measles Indolent systemic mastocytosis Cardiomyopathy Malignant peritoneal neoplasm Genitourinary tract neoplasm Pain in extremity Immune-mediated myositis Developmental hip dysplasia Diabetes mellitus Combined immunodeficiency Retinal vein occlusion Herpes simplex meningitis Apathy More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. IRCCS Humanitas Research Hospital

IRCCS Humanitas Research Hospital

Via Alessandro Manzoni 56, Rozzano, 20089, Italy

Want to learn more about this study or check if you can participate? Contact us.

  • Study of tulisokibart compared to placebo in adults with moderate to severe Crohn’s disease

    Recruiting

    3 1
    Investigated Drugs:
    • Tulisokibart
    Austria Belgium Croatia Czechia Denmark Finland +15

  • Study comparing RMC-6236 and docetaxel in previously treated patients with advanced or metastatic non-small cell lung cancer who have RAS mutations

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE
    • Docetaxel
    Belgium France Germany Ireland Italy The Netherlands +2

  • Study of PF-07275315 to evaluate its effectiveness and safety in adults with moderate-to-severe asthma who have high levels of eosinophils in their blood

    Recruiting

    2 1
    Investigated Diseases:
    • Asthma
    Belgium Bulgaria Czechia Hungary Italy Poland +1

  • Study of carboplatin, paclitaxel, and tislelizumab treatment in patients with resectable locally advanced oral cavity squamous cell carcinoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of the oral cavity
    Investigated Drugs:
    • Carboplatin
    • Paclitaxel
    • Tislelizumab
    Italy

  • Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • Bevacizumab
    • Trastuzumab Deruxtecan
    Austria Belgium Bulgaria Czechia Denmark France +8

  • Study of datopotamab deruxtecan with platinum-based therapy compared to gemcitabine with platinum-based therapy in patients with advanced urothelial cancer after prior treatment

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Transitional cell carcinoma
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Datopotamab Deruxtecan
    Austria Belgium Czechia Denmark France Germany +5

  • Study of BMS-986482 alone or with nivolumab, relatlimab or bevacizumab in patients with advanced solid tumors

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Relatlimab
    • Bevacizumab
    • Nivolumab
    Belgium Denmark France Greece Italy The Netherlands +2

  • Study of BGB-16673 in combination with drug therapy for patients with relapsed or refractory B-cell malignancies

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Chronic lymphocytic leukaemia recurrent
    • Chronic lymphocytic leukaemia refractory
    • Follicular lymphoma stage II
    Investigated Drugs:
    • Glofitamab
    • N-[4-({[(1R,4R)-4-Hydroxy-4-Methylcyclohexyl]Methyl}Amino)-3- Nitrobenzene-1-Sulfonyl]-4-(2-{(2S)-2-[2-(Propan-2-Yl)Phenyl]Pyrrolidin1-Yl}-7-Azaspiro[3.5]Nonan-7-Yl)-2-[(1H-Pyrrolo[2,3-B]Pyridin-5- Yl)Oxy]Benzamide
    • Zanubrutinib
    Germany Italy Poland

  • Efficacy and Safety Study of Paltusotine for Adults with Carcinoid Syndrome due to Well-Differentiated Neuroendocrine Tumors

    Recruiting

    3 1
    Investigated Drugs:
    • Paltusotine
    Belgium Denmark France Germany Ireland Italy +4

  • Study of Bleximenib, Venetoclax, and Azacitidine Treatment for Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible for Intensive Chemotherapy

    Recruiting

    3 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • BLEXIMENIB
    • Azacitidine
    • Venetoclax
    Austria Belgium Czechia Denmark France Germany +6
Previous Page
1 … 11 12 13 14 15 … 69
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!